Aldeyra Therapeutics stock forecast
Aldeyra Therapeutics (137) Stock Forecast & Price Target
137 Analyst Ratings
137 Stock 12 Month Forecast
Average Price Target
€1.78▲(226.99% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Matthew Caufield | H.C. Wainwright | €1.78 | hold | 226.99%Upside | Reiterated | 11/10/26 | ||
| Thomas Shrader | BTIG | €8.02 | buy | 1371.44%Upside | Reiterated | 03/17/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Matthew CaufieldH.C. Wainwright | HoldReiterated€1.78 | 11/10/26 | 226.99%Upside | ||
| Thomas ShraderBTIG | BuyReiterated€8.02 | 03/17/26 | 1371.44%Upside |
Best Analysts Covering Aldeyra Therapeutics
Copying Thomas Shrader's trades and holding each position for 3 Months would result in 54.17% of your transactions generating a profit, with an average return of +11.57% per trade.
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +0.32% per trade.
Copying Thomas Shrader's trades and holding each position for 2 Years would result in 20.83% of your transactions generating a profit, with an average return of -34.87% per trade.
137 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 1 | 3 | 3 | 3 |
In the current month, 137 has received 0 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 137 average Analyst price target in the past 3 months is 1.78.
137 Financial Forecast
137 Earnings Forecast
Next quarter’s earnings estimate for 137 is -EUR 0.08 with a range of ― to ―. The previous quarter’s EPS was -EUR 0.08. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
137 Sales Forecast
Next quarter’s sales forecast for 137 is EUR 0 with a range of ― to ―. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
